74 results
424B3
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement
4:53pm
, and on April 26, 2024, we effected a 75-for-1 reverse split of our Common Stock.
Common Stock
Voting Rights
Holders of our Common Stock are entitled to one … vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our
424B5
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement for primary offering
4:52pm
, every 75 shares of the Company’s pre-reverse split common stock was combined and reclassified as one share of common stock. Proportionate voting rights … submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined
8-K
EX-4.3
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
as Stockholder until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
8-K
EX-4.2
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except
8-K
EX-4.1
9o5xjx
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
8-K
36aj4nq71n57n ce1d
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
8-K
ndwjj56w13o
26 Apr 24
Avenue Therapeutics Announces Reverse Stock Split
4:39pm
424B3
7binz15300czmh8ppoy
2 Feb 24
Prospectus supplement
12:00am
DEF 14C
rsr1k7164hd
29 Jan 24
Information statement
8:00am
PRE 14C
zf7d8oeq
17 Jan 24
Preliminary information
5:05pm
8-K
EX-4.1
l0sys2grfdtrrs7a0bws
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
t8zf8wjc 0f9e
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-4.2
esj3gbrplx5f
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-4.2
ntqctep
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.3
w0ittmrt5zth
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.1
7wa72nrnq nd40uhp
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm